Silicon Valley Gastroenterology
Mountain View, California, 94040, United States
Location status: Recruiting
NCT Number: NCT06298409
We will sample intestinal microbiota using a microbiome sampling capsule in patients with Small Intestinal Bacterial Overgrowth (SIBO)
Interested in participating?
Request Info18 year–80 year
All sexes
Interventional
Phase 1
Mountain View, California, 94040, United States
Location status: Recruiting
Prospective, open-label, single-arm, non-randomized, multi-center study designed to evaluate the effect of the antibiotic rifaximin on the regional composition of the gut microbiota and metabolic profiles of subjects diagnosed with SIBO, using the CapScan collection capsule.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The CapScan collection capsule is a single-use device that collects fluids from the gastrointestinal tract for analysis ex-vivo.
Time frame: 56 days
> 75% of the retrieved CapScan devices to provide at least 3 million metagenomic DNA sequencing reads of gut microbes from the intestinal tract, and at least 900 annotated gut metabolites.
Time frame: 56 days
>75% of the retrieved CapScan devices to provide at least 900 annotated gut metabolites.
Time frame: 56 days
Determine the effect of rifaximin on the regional compositions of the gut microbiota among SIBO patients by assessing the diversity, centroids and distributions of microbial taxa from sequenced CapScan samples of each subject before and after rifaximin at 5 time points.
Time frame: 56 days
Determine the effect of rifaximin on the regional compositions of the gut metabolites among SIBO patients by assessing the changes to metabolite classes and metabolic pathways as measured by LC/MS-MS analysis of CapScan samples for each subject before and after rifaximin at 5 time points.
Contact information is provided by the study sponsor or research team.
Envivo Bio Inc
Industry
Evaluating the Effect of Rifaximin on the Regional Composition of the Gut Microbiota and Metabolic Profiles of Subjects With SIBO Using the CapScan® Collection Capsule
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04506593
Chronic Intestinal Pseudo-obstruction, Colonic Diseases
Indianapolis, Indiana, United States
View Trial DetailsNCT05967871
Small Intestinal Bacterial Overgrowth
Hamilton, Ontario, Canada
View Trial DetailsNCT06317441
Colonic Diseases, Colonic Diseases, Functional
Calgary, Alberta, Canada
View Trial DetailsNCT01822470
Body Weight, Body Weight Changes
Indianapolis, Indiana, United States
View Trial Details